Adverum Biotechnologies Files 8-K Report
| Field | Detail |
|---|---|
| Company | Adverum Biotechnologies, Inc. |
| Form Type | 8-K |
| Filed Date | Sep 22, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Financials
TL;DR
Adverum Biotechnologies filed an 8-K, mostly standard reporting stuff.
AI Summary
On September 22, 2025, Adverum Biotechnologies, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events, indicating ongoing operational and reporting activities for the company. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Adverum Biotechnologies is maintaining its reporting obligations with the SEC, which is standard for publicly traded companies. It suggests ongoing operational status and compliance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and other events, not indicating any immediate material changes or risks.
Key Numbers
- 001-36579 — SEC File Number (Identifies the company's filing with the SEC.)
- 20-5258327 — EIN (Employer Identification Number for tax purposes.)
- 20250922 — Report Date (Date of the earliest event reported in the 8-K.)
Key Players & Entities
- Adverum Biotechnologies, Inc. (company) — Registrant
- Avalanche Biotechnologies, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific 'Other Events' are reported in this 8-K filing?
The provided excerpt does not detail the specific 'Other Events' beyond listing it as an item information category.
What is the significance of the 'Financial Statements and Exhibits' being filed?
This indicates that Adverum Biotechnologies is submitting required financial documentation and supporting exhibits to the SEC as part of its reporting obligations.
When was Adverum Biotechnologies formerly known as Avalanche Biotechnologies, Inc.?
The date of the name change from Avalanche Biotechnologies, Inc. to Adverum Biotechnologies, Inc. was September 21, 2010.
What is the principal executive office address for Adverum Biotechnologies, Inc.?
The principal executive offices are located at 100 Cardinal Way, Redwood City, CA 94063.
What is the SIC code for Adverum Biotechnologies, Inc.?
The Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 725 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2025-09-22 08:11:03
Filing Documents
- d937976d8k.htm (8-K) — 27KB
- d937976dex991.htm (EX-99.1) — 9KB
- 0001193125-25-210068.txt ( ) — 149KB
- advm-20250922.xsd (EX-101.SCH) — 3KB
- advm-20250922_lab.xml (EX-101.LAB) — 17KB
- advm-20250922_pre.xml (EX-101.PRE) — 11KB
- d937976d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release dated September 22, 2025. 104 The cover page of this report has been formatted in Inline XBRL. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ADVERUM BIOTECHNOLOGIES, INC. Date: September 22, 2025 By: /s/ Laurent Fischer Laurent Fischer, M.D. President and Chief Executive Officer